Table 1

Baseline Characteristics Stratified by the Presence of LV-LGE

Overall Cohort
(n = 598)
LV-LGE Absent
(n = 559)
LV-LGE Present
(n = 39)
p Value
Age, yrs64.1 ± 12.063.8 ± 12.065.8 ± 11.70.313
Male360 (60.2)336 (60.1)24 (61.5)0.860
Diabetes81 (13.5)71 (12.7)10 (25.6)0.022
Hypertension366 (61.2)337 (60.3)29 (74.4)0.082
Smoking history166 (27.8)149 (26.7)17 (43.6)0.022
Dyslipidemia172 (28.8)155 (27.7)17 (43.6)0.034
Prior stroke56 (9.4)50 (8.9)6 (15.4)0.183
PAD7 (1.2)5 (0.89)2 (5.1)0.017
Heart failure54 (9.0)45 (8.1)9 (23.1)0.002
Persistent AF262 (43.8)247 (44.2)15 (38.5)0.487
CHADS21.21 ± 1.041.17 ± 1.071.76 ± 1.04<0.001
CHA2DS2-VASc2.14 ± 0.062.09 ± 1.532.85 ± 1.370.003
LA fibrosis, %16.1 ± 10.116.0 ± 10.117.5 ± 10.10.422
LV EF <55%71 (11.9)66 (11.8)5 (12.8)0.850
LA area, cm228.7 ± 7.728.5 ± 7.632.2 ± 8.00.003

Values are mean ± SD or n (%).

AF = atrial fibrillation; EF = ejection fraction; LA = left atrium; LGE = late gadolinium enhancement; LV = left ventricle; PAD = peripheral arterial disease.